BRPI0611885A2 - moduladores opióides tricìclicos - Google Patents

moduladores opióides tricìclicos Download PDF

Info

Publication number: BRPI0611885A2
Authority: BR; Brazil
Prior art keywords: pain; compound; formula; neuralgia; alkanyl
Prior art date: 2005-06-16

Application number

BRPI0611885-2A

Other languages

English (en)

Portuguese (pt)

Inventor

Bart Decorte

Li Liu

Mark Mcdonnell

Jim Mcnally

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-16

Filing date

2006-06-15

Publication date

2010-10-05

2006-06-15 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2010-10-05 Publication of BRPI0611885A2 publication Critical patent/BRPI0611885A2/pt

Links

150000001875 compounds Chemical class 0.000 claims abstract description 327
238000000034 method Methods 0.000 claims abstract description 188
208000002193 Pain Diseases 0.000 claims abstract description 151
230000036407 pain Effects 0.000 claims abstract description 131
239000000203 mixture Substances 0.000 claims abstract description 95
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
201000010099 disease Diseases 0.000 claims abstract description 19
-1 (phenylmethyl) aminocarbonyl Chemical group 0.000 claims description 373
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 121
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 108
125000001072 heteroaryl group Chemical group 0.000 claims description 83
125000001424 substituent group Chemical group 0.000 claims description 80
208000004296 neuralgia Diseases 0.000 claims description 74
150000003839 salts Chemical class 0.000 claims description 62
206010029240 Neuritis Diseases 0.000 claims description 50
239000012453 solvate Substances 0.000 claims description 50
239000001257 hydrogen Substances 0.000 claims description 42
229910052739 hydrogen Inorganic materials 0.000 claims description 42
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 39
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 38
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 35
206010019233 Headaches Diseases 0.000 claims description 34
150000002431 hydrogen Chemical group 0.000 claims description 34
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
125000004076 pyridyl group Chemical group 0.000 claims description 30
229910052799 carbon Inorganic materials 0.000 claims description 28
125000002541 furyl group Chemical group 0.000 claims description 28
125000001544 thienyl group Chemical group 0.000 claims description 27
125000002883 imidazolyl group Chemical group 0.000 claims description 26
229910052736 halogen Inorganic materials 0.000 claims description 24
150000002367 halogens Chemical class 0.000 claims description 24
RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 claims description 23
125000000714 pyrimidinyl group Chemical group 0.000 claims description 23
125000000168 pyrrolyl group Chemical group 0.000 claims description 23
125000003118 aryl group Chemical group 0.000 claims description 22
125000003831 tetrazolyl group Chemical group 0.000 claims description 22
125000003342 alkenyl group Chemical group 0.000 claims description 21
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 21
125000004432 carbon atom Chemical group C* 0.000 claims description 20
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 18
229910052760 oxygen Inorganic materials 0.000 claims description 18
229910052717 sulfur Inorganic materials 0.000 claims description 17
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims description 16
239000003085 diluting agent Substances 0.000 claims description 15
231100000869 headache Toxicity 0.000 claims description 15
125000001041 indolyl group Chemical group 0.000 claims description 15
208000033808 peripheral neuropathy Diseases 0.000 claims description 15
239000000546 pharmaceutical excipient Substances 0.000 claims description 15
125000003373 pyrazinyl group Chemical group 0.000 claims description 15
208000000094 Chronic Pain Diseases 0.000 claims description 14
206010042496 Sunburn Diseases 0.000 claims description 14
125000000304 alkynyl group Chemical group 0.000 claims description 14
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 14
125000001624 naphthyl group Chemical group 0.000 claims description 14
208000021722 neuropathic pain Diseases 0.000 claims description 14
125000003226 pyrazolyl group Chemical group 0.000 claims description 14
206010044652 trigeminal neuralgia Diseases 0.000 claims description 14
206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 13
208000010247 contact dermatitis Diseases 0.000 claims description 13
230000002981 neuropathic effect Effects 0.000 claims description 12
125000002098 pyridazinyl group Chemical group 0.000 claims description 12
206010028980 Neoplasm Diseases 0.000 claims description 11
125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 claims description 11
125000001769 aryl amino group Chemical group 0.000 claims description 11
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
206010065390 Inflammatory pain Diseases 0.000 claims description 10
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 claims description 10
125000004423 acyloxy group Chemical group 0.000 claims description 10
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 10
108700023159 delta Opioid Receptors Proteins 0.000 claims description 10
102000048124 delta Opioid Receptors Human genes 0.000 claims description 10
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
239000011737 fluorine Substances 0.000 claims description 9
229910052731 fluorine Inorganic materials 0.000 claims description 9
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 9
230000001404 mediated effect Effects 0.000 claims description 9
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 9
125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 9
208000009935 visceral pain Diseases 0.000 claims description 9
208000007848 Alcoholism Diseases 0.000 claims description 8
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 8
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
208000018737 Parkinson disease Diseases 0.000 claims description 8
125000003545 alkoxy group Chemical group 0.000 claims description 8
208000010668 atopic eczema Diseases 0.000 claims description 8
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 8
125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims description 8
201000001119 neuropathy Diseases 0.000 claims description 8
208000023504 respiratory system disease Diseases 0.000 claims description 8
208000011117 substance-related disease Diseases 0.000 claims description 8
208000011580 syndromic disease Diseases 0.000 claims description 8
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 7
206010063409 Acarodermatitis Diseases 0.000 claims description 7
206010003399 Arthropod bite Diseases 0.000 claims description 7
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 7
201000006390 Brachial Plexus Neuritis Diseases 0.000 claims description 7
206010068065 Burning mouth syndrome Diseases 0.000 claims description 7
208000001387 Causalgia Diseases 0.000 claims description 7
206010007882 Cellulitis Diseases 0.000 claims description 7
208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 7
201000004624 Dermatitis Diseases 0.000 claims description 7
206010012442 Dermatitis contact Diseases 0.000 claims description 7
206010012735 Diarrhoea Diseases 0.000 claims description 7
206010013654 Drug abuse Diseases 0.000 claims description 7
208000004232 Enteritis Diseases 0.000 claims description 7
208000001640 Fibromyalgia Diseases 0.000 claims description 7
208000007882 Gastritis Diseases 0.000 claims description 7
208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims description 7
208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
208000006877 Insect Bites and Stings Diseases 0.000 claims description 7
206010049949 Intercostal neuralgia Diseases 0.000 claims description 7
208000005615 Interstitial Cystitis Diseases 0.000 claims description 7
208000007914 Labor Pain Diseases 0.000 claims description 7
208000035945 Labour pain Diseases 0.000 claims description 7
206010049567 Miller Fisher syndrome Diseases 0.000 claims description 7
208000002472 Morton Neuroma Diseases 0.000 claims description 7
208000020059 Morton neuralgia Diseases 0.000 claims description 7
206010028116 Mucosal inflammation Diseases 0.000 claims description 7
201000010927 Mucositis Diseases 0.000 claims description 7
208000000112 Myalgia Diseases 0.000 claims description 7
208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 7
206010029279 Neurogenic bladder Diseases 0.000 claims description 7
206010036105 Polyneuropathy Diseases 0.000 claims description 7
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 7
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 7
241000447727 Scabies Species 0.000 claims description 7
208000004078 Snake Bites Diseases 0.000 claims description 7
208000003589 Spider Bites Diseases 0.000 claims description 7
206010043269 Tension headache Diseases 0.000 claims description 7
208000008548 Tension-Type Headache Diseases 0.000 claims description 7
206010001584 alcohol abuse Diseases 0.000 claims description 7
208000025746 alcohol use disease Diseases 0.000 claims description 7
230000002146 bilateral effect Effects 0.000 claims description 7
230000035606 childbirth Effects 0.000 claims description 7
201000001352 cholecystitis Diseases 0.000 claims description 7
208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 7
201000005442 glossopharyngeal neuralgia Diseases 0.000 claims description 7
230000009610 hypersensitivity Effects 0.000 claims description 7
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 7
208000014674 injury Diseases 0.000 claims description 7
208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 7
125000001786 isothiazolyl group Chemical group 0.000 claims description 7
230000001617 migratory effect Effects 0.000 claims description 7
201000009985 neuronitis Diseases 0.000 claims description 7
201000008482 osteoarthritis Diseases 0.000 claims description 7
125000002971 oxazolyl group Chemical group 0.000 claims description 7
208000019629 polyneuritis Diseases 0.000 claims description 7
206010036596 premature ejaculation Diseases 0.000 claims description 7
208000037821 progressive disease Diseases 0.000 claims description 7
206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
206010039083 rhinitis Diseases 0.000 claims description 7
208000005687 scabies Diseases 0.000 claims description 7
210000004872 soft tissue Anatomy 0.000 claims description 7
238000001356 surgical procedure Methods 0.000 claims description 7
230000000451 tissue damage Effects 0.000 claims description 7
231100000827 tissue damage Toxicity 0.000 claims description 7
230000008733 trauma Effects 0.000 claims description 7
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
206010058019 Cancer Pain Diseases 0.000 claims description 6
206010054874 Sphenopalatine neuralgia Diseases 0.000 claims description 6
208000005298 acute pain Diseases 0.000 claims description 6
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
125000004122 cyclic group Chemical group 0.000 claims description 6
125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims description 6
125000000842 isoxazolyl group Chemical group 0.000 claims description 6
125000005394 methallyl group Chemical group 0.000 claims description 6
102000051367 mu Opioid Receptors Human genes 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
208000004371 toothache Diseases 0.000 claims description 6
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
206010054048 Postoperative ileus Diseases 0.000 claims description 5
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 5
230000001684 chronic effect Effects 0.000 claims description 5
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
125000000335 thiazolyl group Chemical group 0.000 claims description 5
108020001612 μ-opioid receptors Proteins 0.000 claims description 5
206010027599 migraine Diseases 0.000 claims description 4
125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 3
125000001589 carboacyl group Chemical group 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
230000002175 menstrual effect Effects 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
230000009692 acute damage Effects 0.000 claims description 2
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims 17
241000124008 Mammalia Species 0.000 claims 16
208000006820 Arthralgia Diseases 0.000 claims 6
208000024172 Cardiovascular disease Diseases 0.000 claims 6
208000006561 Cluster Headache Diseases 0.000 claims 6
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 6
208000022559 Inflammatory bowel disease Diseases 0.000 claims 6
208000003435 Optic Neuritis Diseases 0.000 claims 6
201000007100 Pharyngitis Diseases 0.000 claims 6
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 6
208000008765 Sciatica Diseases 0.000 claims 6
206010040744 Sinus headache Diseases 0.000 claims 6
206010046543 Urinary incontinence Diseases 0.000 claims 6
208000018912 cluster headache syndrome Diseases 0.000 claims 6
206010012601 diabetes mellitus Diseases 0.000 claims 6
206010063491 Herpes zoster oticus Diseases 0.000 claims 5
210000000481 breast Anatomy 0.000 claims 5
201000011349 geniculate herpes zoster Diseases 0.000 claims 5
206010013935 Dysmenorrhoea Diseases 0.000 claims 4
125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
125000001475 halogen functional group Chemical group 0.000 claims 2
230000002980 postoperative effect Effects 0.000 claims 2
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 2
LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 claims 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
210000004958 brain cell Anatomy 0.000 claims 1
125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
230000007823 neuropathy Effects 0.000 claims 1
102000003840 Opioid Receptors Human genes 0.000 abstract description 7
108090000137 Opioid Receptors Proteins 0.000 abstract description 7
239000000243 solution Substances 0.000 description 66
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
239000003814 drug Substances 0.000 description 42
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
230000006978 adaptation Effects 0.000 description 28
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
238000006243 chemical reaction Methods 0.000 description 23
239000002904 solvent Substances 0.000 description 20
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
238000002360 preparation method Methods 0.000 description 17
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
210000004556 brain Anatomy 0.000 description 16
238000010828 elution Methods 0.000 description 16
150000001721 carbon Chemical group 0.000 description 15
229940079593 drug Drugs 0.000 description 15
239000003480 eluent Substances 0.000 description 14
238000011160 research Methods 0.000 description 14
125000000217 alkyl group Chemical group 0.000 description 13
150000003254 radicals Chemical class 0.000 description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
230000027455 binding Effects 0.000 description 12
238000001914 filtration Methods 0.000 description 12
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 12
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
239000007787 solid Substances 0.000 description 12
239000002253 acid Substances 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
230000000694 effects Effects 0.000 description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
239000012044 organic layer Substances 0.000 description 11
238000010992 reflux Methods 0.000 description 11
238000000926 separation method Methods 0.000 description 11
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Substances FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 11
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
125000003710 aryl alkyl group Chemical group 0.000 description 10
239000003054 catalyst Substances 0.000 description 10
238000004440 column chromatography Methods 0.000 description 10
239000002274 desiccant Substances 0.000 description 10
229910052763 palladium Inorganic materials 0.000 description 10
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
239000007983 Tris buffer Substances 0.000 description 9
239000000908 ammonium hydroxide Substances 0.000 description 9
239000003446 ligand Substances 0.000 description 9
239000012074 organic phase Substances 0.000 description 9
229910000027 potassium carbonate Inorganic materials 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
239000000725 suspension Substances 0.000 description 9
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
OCRPZVVAUXUZID-UHFFFAOYSA-N 9-oxoxanthene-4-carboxylic acid Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C(C(=O)O)=CC=C2 OCRPZVVAUXUZID-UHFFFAOYSA-N 0.000 description 8
239000012131 assay buffer Substances 0.000 description 8
229910052943 magnesium sulfate Inorganic materials 0.000 description 8
235000019341 magnesium sulphate Nutrition 0.000 description 8
239000000463 material Substances 0.000 description 8
239000012528 membrane Substances 0.000 description 8
239000003960 organic solvent Substances 0.000 description 8
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 7
238000001704 evaporation Methods 0.000 description 7
230000008020 evaporation Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
KBQFPPUAIJHDCO-UHFFFAOYSA-N 4-Hydroxyxanthone Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C(O)=CC=C2 KBQFPPUAIJHDCO-UHFFFAOYSA-N 0.000 description 6
ZAPCXGOIKZJMTI-UHFFFAOYSA-N 9-[8-[(2-methylpropan-2-yl)oxycarbonyl]-8-azabicyclo[3.2.1]octan-3-ylidene]xanthene-4-carboxylic acid Chemical compound C12=CC=CC=C2OC2=C(C(O)=O)C=CC=C2C1=C(C1)CC2CCC1N2C(=O)OC(C)(C)C ZAPCXGOIKZJMTI-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
239000000730 antalgic agent Substances 0.000 description 6
150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
238000001816 cooling Methods 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 6
125000005842 heteroatom Chemical group 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
229960005181 morphine Drugs 0.000 description 6
229940127240 opiate Drugs 0.000 description 6
239000008188 pellet Substances 0.000 description 6
229920000137 polyphosphoric acid Polymers 0.000 description 6
238000000159 protein binding assay Methods 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000004044 response Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
125000003396 thiol group Chemical group [H]S* 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
MHSALILWXLQJDM-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)xanthene-4-carboxamide Chemical compound C1C(N2)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2C(=O)N MHSALILWXLQJDM-UHFFFAOYSA-N 0.000 description 5
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
208000004454 Hyperalgesia Diseases 0.000 description 5
241000700159 Rattus Species 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
239000000556 agonist Substances 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
229940035676 analgesics Drugs 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
150000002576 ketones Chemical class 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
229940044601 receptor agonist Drugs 0.000 description 5
239000000018 receptor agonist Substances 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
239000003826 tablet Substances 0.000 description 5
230000009466 transformation Effects 0.000 description 5
AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 4
SYEHHMRXODULBY-UHFFFAOYSA-N 4-methoxyxanthen-9-one Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C(OC)=CC=C2 SYEHHMRXODULBY-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
208000035154 Hyperesthesia Diseases 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
125000003282 alkyl amino group Chemical group 0.000 description 4
230000000202 analgesic effect Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
229910000024 caesium carbonate Inorganic materials 0.000 description 4
150000003857 carboxamides Chemical class 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
239000000460 chlorine Chemical group 0.000 description 4
238000002983 circular dichroism Methods 0.000 description 4
125000004093 cyano group Chemical group *C#N 0.000 description 4
LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 4
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
230000035479 physiological effects, processes and functions Effects 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 3
VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 3
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
SXSZKCVTSJZHHV-UHFFFAOYSA-N 2-(2-bromophenoxy)benzonitrile Chemical compound BrC1=CC=CC=C1OC1=CC=CC=C1C#N SXSZKCVTSJZHHV-UHFFFAOYSA-N 0.000 description 3
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
UITUKEBIZYAQIU-UHFFFAOYSA-N 4-aminoxanthen-9-one Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C(N)=CC=C2 UITUKEBIZYAQIU-UHFFFAOYSA-N 0.000 description 3
IJFKXPBJTZOWMN-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)-n'-hydroxyxanthene-4-carboximidamide Chemical compound C1C(N2)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2C(=N)NO IJFKXPBJTZOWMN-UHFFFAOYSA-N 0.000 description 3
VLNPJZQJSJFLKE-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)-n-(2-phenylethyl)xanthene-4-carboxamide Chemical compound C=1C=CC=2C(=C3CC4CCC(N4)C3)C3=CC=CC=C3OC=2C=1C(=O)NCCC1=CC=CC=C1 VLNPJZQJSJFLKE-UHFFFAOYSA-N 0.000 description 3
JPSFXBVMGPBEJU-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)-n-benzylxanthene-4-carboxamide Chemical compound C=1C=CC=2C(=C3CC4CCC(N4)C3)C3=CC=CC=C3OC=2C=1C(=O)NCC1=CC=CC=C1 JPSFXBVMGPBEJU-UHFFFAOYSA-N 0.000 description 3
QQOWJQDAXMPFOU-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)-n-phenylxanthene-4-carboxamide Chemical compound C=1C=CC=2C(=C3CC4CCC(N4)C3)C3=CC=CC=C3OC=2C=1C(=O)NC1=CC=CC=C1 QQOWJQDAXMPFOU-UHFFFAOYSA-N 0.000 description 3
QCQCWSJMNHMCFU-UHFFFAOYSA-N 9-[8-(2,2,2-trifluoroacetyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthene-4-carbonitrile Chemical compound C12=CC=CC=C2OC2=C(C#N)C=CC=C2C1=C(C1)CC2CCC1N2C(=O)C(F)(F)F QCQCWSJMNHMCFU-UHFFFAOYSA-N 0.000 description 3
TUFVXSIXGVJIOB-UHFFFAOYSA-N 9-[8-(2,2,2-trifluoroacetyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthene-4-carboxamide Chemical compound C1C(N2C(=O)C(F)(F)F)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2C(=O)N TUFVXSIXGVJIOB-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
239000004215 Carbon black (E152) Substances 0.000 description 3
206010011224 Cough Diseases 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
238000005727 Friedel-Crafts reaction Methods 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
239000002841 Lewis acid Substances 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000019695 Migraine disease Diseases 0.000 description 3
229940127450 Opioid Agonists Drugs 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
241001582429 Tetracis Species 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
DEADSYOZCMPTOR-UHFFFAOYSA-N [9-[8-(2,2,2-trifluoroacetyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthen-4-yl] trifluoromethanesulfonate Chemical compound C12=CC=CC=C2OC2=C(OS(=O)(=O)C(F)(F)F)C=CC=C2C1=C(C1)CC2CCC1N2C(=O)C(F)(F)F DEADSYOZCMPTOR-UHFFFAOYSA-N 0.000 description 3
QTHBHENRKBEYLV-UHFFFAOYSA-N acetonitrile;copper Chemical compound [Cu].CC#N QTHBHENRKBEYLV-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
150000008044 alkali metal hydroxides Chemical class 0.000 description 3
229930013930 alkaloid Natural products 0.000 description 3
230000001754 anti-pyretic effect Effects 0.000 description 3
239000002221 antipyretic Substances 0.000 description 3
239000012300 argon atmosphere Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
239000012267 brine Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
239000011521 glass Substances 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
150000007529 inorganic bases Chemical class 0.000 description 3
150000007517 lewis acids Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
NQFYUFCYCHRTQB-UHFFFAOYSA-N methyl 9-[8-(2,2,2-trifluoroacetyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthene-4-carboxylate Chemical compound C1C(N2C(=O)C(F)(F)F)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2C(=O)OC NQFYUFCYCHRTQB-UHFFFAOYSA-N 0.000 description 3
JFLAGSLJBYOMAF-UHFFFAOYSA-N methyl 9-oxoxanthene-4-carboxylate Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C(C(=O)OC)=CC=C2 JFLAGSLJBYOMAF-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
230000036403 neuro physiology Effects 0.000 description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
230000000269 nucleophilic effect Effects 0.000 description 3
229940005483 opioid analgesics Drugs 0.000 description 3
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
238000002694 regional anesthesia Methods 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
238000010189 synthetic method Methods 0.000 description 3
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 2
COXVPYKZDDKVRF-ULQDDVLXSA-N (4,4-difluorocyclohexyl)methyl N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=O)NC(=O)OCC2CCC(CC2)(F)F COXVPYKZDDKVRF-ULQDDVLXSA-N 0.000 description 2
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
QLBCHIMJDKDSGD-UHFFFAOYSA-N 2-(2-bromophenoxy)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1Br QLBCHIMJDKDSGD-UHFFFAOYSA-N 0.000 description 2
LFWIIPSSDWXVJZ-UHFFFAOYSA-N 2-(2-methoxyphenoxy)benzoic acid Chemical compound COC1=CC=CC=C1OC1=CC=CC=C1C(O)=O LFWIIPSSDWXVJZ-UHFFFAOYSA-N 0.000 description 2
ORQHHLPTMSGMQT-UHFFFAOYSA-N 2-[4-(5-fluoropyridin-2-yl)piperazin-1-yl]-n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide Chemical compound N1=CC(F)=CC=C1N1CCN(CC(=O)NC=2SC=3CCCCC=3N=2)CC1 ORQHHLPTMSGMQT-UHFFFAOYSA-N 0.000 description 2
XRXMNWGCKISMOH-UHFFFAOYSA-N 2-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Br XRXMNWGCKISMOH-UHFFFAOYSA-N 0.000 description 2
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 2
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
HIICXSGETIAAGP-UHFFFAOYSA-N 3-nitro-2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1OC1=CC=CC=C1 HIICXSGETIAAGP-UHFFFAOYSA-N 0.000 description 2
IPOXERKIEPWMGE-UHFFFAOYSA-N 4-nitroxanthen-9-one Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C([N+](=O)[O-])=CC=C2 IPOXERKIEPWMGE-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
VBYDPWVDMQSJFU-UHFFFAOYSA-N 9-[8-(furan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthen-4-ol Chemical compound C12=CC=CC=C2OC=2C(O)=CC=CC=2C1=C(C1)CC2CCC1N2CC=1C=COC=1 VBYDPWVDMQSJFU-UHFFFAOYSA-N 0.000 description 2
YYOZVGKMCSNCAW-UHFFFAOYSA-N 9-[8-(pyridin-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthene-4-carboxamide Chemical compound C12=CC=CC=C2OC=2C(C(=O)N)=CC=CC=2C1=C(C1)CC2CCC1N2CC1=CC=CC=N1 YYOZVGKMCSNCAW-UHFFFAOYSA-N 0.000 description 2
UVFLVMYXEOXFNP-UHFFFAOYSA-N 9-oxothioxanthene-4-carboxamide Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C(=O)N)=CC=C2 UVFLVMYXEOXFNP-UHFFFAOYSA-N 0.000 description 2
OTPIPHJWVKNZOA-UHFFFAOYSA-N 9-oxothioxanthene-4-carboxylic acid Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C(=O)O)=CC=C2 OTPIPHJWVKNZOA-UHFFFAOYSA-N 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000288030 Coturnix coturnix Species 0.000 description 2
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
108010049140 Endorphins Proteins 0.000 description 2
102000009025 Endorphins Human genes 0.000 description 2
239000004593 Epoxy Substances 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
108010093625 Opioid Peptides Proteins 0.000 description 2
102000001490 Opioid Peptides Human genes 0.000 description 2
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
208000004756 Respiratory Insufficiency Diseases 0.000 description 2
206010038678 Respiratory depression Diseases 0.000 description 2
244000007853 Sarothamnus scoparius Species 0.000 description 2
206010041349 Somnolence Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
150000003797 alkaloid derivatives Chemical class 0.000 description 2
150000001336 alkenes Chemical class 0.000 description 2
150000001345 alkine derivatives Chemical class 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
239000011324 bead Substances 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
229910052796 boron Inorganic materials 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
239000002327 cardiovascular agent Substances 0.000 description 2
229940125692 cardiovascular agent Drugs 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125797 compound 12 Drugs 0.000 description 2
229940126543 compound 14 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
239000007933 dermal patch Substances 0.000 description 2
SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
238000002224 dissection Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
229960001867 guaiacol Drugs 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
230000036737 immune function Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
YMNGWDYNLWQVDN-UHFFFAOYSA-N n'-hydroxy-9-[8-(2,2,2-trifluoroacetyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthene-4-carboximidamide Chemical compound C1C(N2C(=O)C(F)(F)F)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2C(=N)NO YMNGWDYNLWQVDN-UHFFFAOYSA-N 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000008693 nausea Effects 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003399 opiate peptide Substances 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
229940116357 potassium thiocyanate Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 2
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000006798 ring closing metathesis reaction Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
150000003568 thioethers Chemical class 0.000 description 2
238000000844 transformation Methods 0.000 description 2
229910052723 transition metal Inorganic materials 0.000 description 2
150000003624 transition metals Chemical class 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 2
238000003828 vacuum filtration Methods 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical class C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
GNPHAOQLHRZODS-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[butyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CCCC)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CCCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 GNPHAOQLHRZODS-ZQWQDMLBSA-N 0.000 description 1
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
SBTVLCPCSXMWIQ-UHFFFAOYSA-N (3,5-dimethylphenyl) carbamate Chemical compound CC1=CC(C)=CC(OC(N)=O)=C1 SBTVLCPCSXMWIQ-UHFFFAOYSA-N 0.000 description 1
PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
MNIPVWXWSPXERA-IDNZQHFXSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecanoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)CCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 MNIPVWXWSPXERA-IDNZQHFXSA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 description 1
HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 1
OXDSKEQSEGDAFN-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenylmethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1 OXDSKEQSEGDAFN-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
YPJMOVVQKBFRNH-UHFFFAOYSA-N 1-(9-ethylcarbazol-3-yl)-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1CNCC1=CC=CC=N1 YPJMOVVQKBFRNH-UHFFFAOYSA-N 0.000 description 1
QCPCQUBUGWSDIV-UHFFFAOYSA-N 1-[3-[4-(benzhydrylideneamino)xanthen-9-ylidene]-8-azabicyclo[3.2.1]octan-8-yl]-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)N1C(C2)CCC1CC2=C(C1=CC=C2)C3=CC=CC=C3OC1=C2N=C(C=1C=CC=CC=1)C1=CC=CC=C1 QCPCQUBUGWSDIV-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
UAXNXOMKCGKNCI-UHFFFAOYSA-N 1-diphenylphosphanylethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)P(C=1C=CC=CC=1)C1=CC=CC=C1 UAXNXOMKCGKNCI-UHFFFAOYSA-N 0.000 description 1
HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
LYUPJHVGLFETDG-UHFFFAOYSA-N 1-phenylbutan-2-ol Chemical compound CCC(O)CC1=CC=CC=C1 LYUPJHVGLFETDG-UHFFFAOYSA-N 0.000 description 1
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 1
UUDALWDRIFYZPM-UHFFFAOYSA-N 1h-pyridine-2,4-dione Chemical group O=C1CC(=O)C=CN1 UUDALWDRIFYZPM-UHFFFAOYSA-N 0.000 description 1
FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
FMGHXZOIAXNGOL-UHFFFAOYSA-N 2-(2-cyanophenyl)sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1SC1=CC=CC=C1C#N FMGHXZOIAXNGOL-UHFFFAOYSA-N 0.000 description 1
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 1
QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 1
VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
JRQDVRIQJJPHEQ-UHFFFAOYSA-N 3970-35-2 Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1Cl JRQDVRIQJJPHEQ-UHFFFAOYSA-N 0.000 description 1
LIDUGWDLSDKCLM-CSKARUKUSA-N 4-[[3-[[[(e)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]methyl-dimethylsilyl]benzonitrile Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC(OC[Si](C)(C)C=2C=CC(=CC=2)C#N)=C1 LIDUGWDLSDKCLM-CSKARUKUSA-N 0.000 description 1
UBPSDNHQRRCBTG-UHFFFAOYSA-N 4-bromoxanthen-9-one Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C(Br)=CC=C2 UBPSDNHQRRCBTG-UHFFFAOYSA-N 0.000 description 1
FPIWJQQRYHEICX-UHFFFAOYSA-N 6,11-dihydrobenzo[c][1]benzoxepine Chemical class C1OC2=CC=CC=C2CC2=CC=CC=C12 FPIWJQQRYHEICX-UHFFFAOYSA-N 0.000 description 1
NXWRQWPMYVTHMN-UHFFFAOYSA-N 6-(8-benzyl-8-azabicyclo[3.2.1]octan-3-ylidene)chromeno[2,3-e][1,3]benzothiazol-2-amine Chemical compound C12=CC=C3SC(N)=NC3=C2OC2=CC=CC=C2C1=C(C1)CC2CCC1N2CC1=CC=CC=C1 NXWRQWPMYVTHMN-UHFFFAOYSA-N 0.000 description 1
FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 description 1
HJCUTNIGJHJGCF-UHFFFAOYSA-N 9,10-dihydroacridine Chemical class C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 1
LRZUVRCSAXUVHZ-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)-n,n-dimethylxanthene-4-carboxamide Chemical compound C1C(N2)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2C(=O)N(C)C LRZUVRCSAXUVHZ-UHFFFAOYSA-N 0.000 description 1
WWDVBPAIEPBURJ-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)-n-[2-(dimethylamino)ethyl]xanthene-4-carboxamide Chemical compound C1C(N2)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2C(=O)NCCN(C)C WWDVBPAIEPBURJ-UHFFFAOYSA-N 0.000 description 1
AXTSGDYTRZBPCT-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)-n-methylxanthene-4-carboxamide Chemical compound C1C(N2)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2C(=O)NC AXTSGDYTRZBPCT-UHFFFAOYSA-N 0.000 description 1
JXHJVEZTJXDECQ-UHFFFAOYSA-N 9-(8-azabicyclo[3.2.1]octan-3-ylidene)xanthen-4-ol Chemical compound C1C(N2)CCC2CC1=C1C2=CC=CC=C2OC2=C1C=CC=C2O JXHJVEZTJXDECQ-UHFFFAOYSA-N 0.000 description 1
JIYPUEZSSJAXBO-UHFFFAOYSA-N 9-Azabicyclo[3.3.1]nonan-3-one Chemical compound C1CCC2CC(=O)CC1N2 JIYPUEZSSJAXBO-UHFFFAOYSA-N 0.000 description 1
NAWDCSRHJZZGLZ-UHFFFAOYSA-N 9-[8-(furan-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-ylidene]-n'-hydroxyxanthene-4-carboximidamide Chemical compound C12=CC=CC=C2OC=2C(C(=N)NO)=CC=CC=2C1=C(C1)CC2CCC1N2CC1=CC=CO1 NAWDCSRHJZZGLZ-UHFFFAOYSA-N 0.000 description 1
PGGHVTLVCHGQSL-UHFFFAOYSA-N 9-[8-(furan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthene-4-carboxamide Chemical compound C12=CC=CC=C2OC=2C(C(=O)N)=CC=CC=2C1=C(C1)CC2CCC1N2CC=1C=COC=1 PGGHVTLVCHGQSL-UHFFFAOYSA-N 0.000 description 1
JCCCMWIJDWTLJA-UHFFFAOYSA-N 9-[8-(pyridin-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-ylidene]xanthen-4-ol Chemical compound C12=CC=CC=C2OC=2C(O)=CC=CC=2C1=C(C1)CC2CCC1N2CC1=CC=CC=N1 JCCCMWIJDWTLJA-UHFFFAOYSA-N 0.000 description 1
KFNHWDSFOUFZRT-UHFFFAOYSA-N 9-oxoxanthene-4-carboxamide Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C(C(=O)N)=CC=C2 KFNHWDSFOUFZRT-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
DGJMHKMYSDYOFP-MRXNPFEDSA-N C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O Chemical compound C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O DGJMHKMYSDYOFP-MRXNPFEDSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241001274237 Caranx latus Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
241000207199 Citrus Species 0.000 description 1
CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
229940127007 Compound 39 Drugs 0.000 description 1
229940126650 Compound 3f Drugs 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 description 1
MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241001539473 Euphoria Species 0.000 description 1
206010015535 Euphoric mood Diseases 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
241001024304 Mino Species 0.000 description 1
206010027951 Mood swings Diseases 0.000 description 1
101100058506 Mus musculus Bloc1s5 gene Proteins 0.000 description 1
101100171815 Mus musculus Efnb1 gene Proteins 0.000 description 1
101000835625 Mus musculus Tubulin-specific chaperone A Proteins 0.000 description 1
XJTWGMHOQKGBDO-GOSISDBHSA-N N-[(3-Fluorophenyl)methyl]-1-[(1r)-1-Naphthalen-1-Ylethyl]piperidine-4-Carboxamide Chemical group C1CN([C@H](C)C=2C3=CC=CC=C3C=CC=2)CCC1C(=O)NCC1=CC=CC(F)=C1 XJTWGMHOQKGBDO-GOSISDBHSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
WIYUZYBFCWCCQJ-IFKAHUTRSA-N Naltrindole Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3NC=25)O)CC1)O)CC1CC1 WIYUZYBFCWCCQJ-IFKAHUTRSA-N 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
229940123257 Opioid receptor antagonist Drugs 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
101150003085 Pdcl gene Proteins 0.000 description 1
208000004983 Phantom Limb Diseases 0.000 description 1
206010056238 Phantom pain Diseases 0.000 description 1
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
239000005922 Phosphane Substances 0.000 description 1
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
235000014443 Pyrus communis Nutrition 0.000 description 1
101100163901 Rattus norvegicus Asic2 gene Proteins 0.000 description 1
229940125907 SJ995973 Drugs 0.000 description 1
238000003436 Schotten-Baumann reaction Methods 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
241001105470 Valenzuela Species 0.000 description 1
241001660687 Xantho Species 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
ORWKVZNEPHTCQE-UHFFFAOYSA-N acetic formic anhydride Chemical compound CC(=O)OC=O ORWKVZNEPHTCQE-UHFFFAOYSA-N 0.000 description 1
HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
239000012445 acidic reagent Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
238000007083 alkoxycarbonylation reaction Methods 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
125000001118 alkylidene group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
150000001448 anilines Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000005018 aryl alkenyl group Chemical group 0.000 description 1
125000005015 aryl alkynyl group Chemical group 0.000 description 1
150000001502 aryl halides Chemical class 0.000 description 1
150000005840 aryl radicals Chemical class 0.000 description 1
KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
ANTGQBPGYZDWAW-UHFFFAOYSA-N azane;1,4-dioxane Chemical compound N.C1COCCO1 ANTGQBPGYZDWAW-UHFFFAOYSA-N 0.000 description 1
125000005337 azoxy group Chemical group [N+]([O-])(=N*)* 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
239000012965 benzophenone Substances 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
125000005510 but-1-en-2-yl group Chemical group 0.000 description 1
125000005514 but-1-yn-3-yl group Chemical group 0.000 description 1
OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003940 butylamines Chemical class 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
239000012659 cardioprotective agent Substances 0.000 description 1
229940045200 cardioprotective agent Drugs 0.000 description 1
238000013130 cardiovascular surgery Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000010531 catalytic reduction reaction Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
YBFBENHWPRGUMU-UHFFFAOYSA-N chembl398496 Chemical compound OC(=O)C1=CC=CC=C1NC(=O)N1CCN(C=2N=C3C=CC(O)=CC3=NC=2)CC1 YBFBENHWPRGUMU-UHFFFAOYSA-N 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000001142 circular dichroism spectrum Methods 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940125807 compound 37 Drugs 0.000 description 1
229940125796 compound 3d Drugs 0.000 description 1
229940126540 compound 41 Drugs 0.000 description 1
229940125936 compound 42 Drugs 0.000 description 1
229940125880 compound 4j Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
229940125801 compound 7f Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000000039 congener Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000006310 cycloalkyl amino group Chemical group 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
230000020335 dealkylation Effects 0.000 description 1
238000006900 dealkylation reaction Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical compound Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
229950002494 diprenorphine Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000003118 drug derivative Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000010410 dusting Methods 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
229950004155 etorphine Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
150000004820 halides Chemical group 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000004404 heteroalkyl group Chemical group 0.000 description 1
125000004446 heteroarylalkyl group Chemical group 0.000 description 1
QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
208000022119 inability to concentrate Diseases 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
102000048260 kappa Opioid Receptors Human genes 0.000 description 1
239000008101 lactose Substances 0.000 description 1
MKXZASYAUGDDCJ-CGTJXYLNSA-N levomethorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(C)[C@@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-CGTJXYLNSA-N 0.000 description 1
QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 1
OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000000956 olfactory bulb Anatomy 0.000 description 1
210000001010 olfactory tubercle Anatomy 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
229960002195 perazine Drugs 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
229910000064 phosphane Inorganic materials 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000004237 preparative chromatography Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
125000001749 primary amide group Chemical group 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
RHWSKVCZXBAWLZ-OCAPTIKFSA-N pseudopelletierine Chemical compound C1CC[C@@H]2CC(=O)C[C@H]1N2C RHWSKVCZXBAWLZ-OCAPTIKFSA-N 0.000 description 1
RHWSKVCZXBAWLZ-UHFFFAOYSA-N pseudopelletierine hydrochloride Natural products C1CCC2CC(=O)CC1N2C RHWSKVCZXBAWLZ-UHFFFAOYSA-N 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000010926 purge Methods 0.000 description 1
DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
208000007771 sciatic neuropathy Diseases 0.000 description 1
150000003334 secondary amides Chemical class 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
BXBUVIPNRGDTNE-UHFFFAOYSA-N sodium;hydrobromide Chemical compound [Na].Br BXBUVIPNRGDTNE-UHFFFAOYSA-N 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
150000003511 tertiary amides Chemical class 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
125000002769 thiazolinyl group Chemical group 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000005490 tosylate group Chemical group 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
XPDWGBQVDMORPB-UHFFFAOYSA-N trifluoromethane acid Natural products FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
125000005580 triphenylene group Chemical group 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
239000002550 vasoactive agent Substances 0.000 description 1
230000004304 visual acuity Effects 0.000 description 1
229940045860 white wax Drugs 0.000 description 1
CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
108020001588 κ-opioid receptors Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Addiction (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)

BRPI0611885-2A 2005-06-16 2006-06-15 moduladores opióides tricìclicos BRPI0611885A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US69110105P	2005-06-16	2005-06-16
US60/691,101		2005-06-16
PCT/US2006/023429 WO2006138528A2 (en)	2005-06-16	2006-06-15	Tricyclic opioid modulators

Publications (1)

Publication Number	Publication Date
BRPI0611885A2 true BRPI0611885A2 (pt)	2010-10-05

Family

ID=37334600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0611885-2A BRPI0611885A2 (pt)	2005-06-16	2006-06-15	moduladores opióides tricìclicos

Country Status (13)

Country	Link
US (2)	US7582650B2 (de)
EP (1)	EP1896467B1 (de)
JP (1)	JP2008543866A (de)
CN (1)	CN101243079A (de)
AR (1)	AR057374A1 (de)
AT (1)	ATE490251T1 (de)
AU (1)	AU2006259273A1 (de)
BR (1)	BRPI0611885A2 (de)
CA (1)	CA2612491A1 (de)
DE (1)	DE602006018604D1 (de)
RU (1)	RU2008101667A (de)
TW (1)	TW200716134A (de)
WO (1)	WO2006138528A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7589103B2 (en)	2003-06-27	2009-09-15	Janssen Pharmaceutica N.V.	Tricyclic-bridged piperidinylidene derivatives as 8-opioid modulators
KR20080027216A (ko) *	2004-08-05	2008-03-26	얀센 파마슈티카 엔.브이.	트리사이클릭 δ-오피오이드 조절자
CA2592462A1 (en) *	2004-12-22	2006-06-29	Janssen Pharmaceutica N.V.	Tricyclic delta-opioid modulators
ATE432279T1 (de) *	2004-12-22	2009-06-15	Janssen Pharmaceutica Nv	Tricyclische delta-opioid-modulatoren
JP2008525483A (ja) *	2004-12-22	2008-07-17	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	三環式δ−オピオイド調節剤
JP2008526878A (ja) *	2005-01-06	2008-07-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	三環式δ−オピオイド調節剤
US7582650B2 (en) *	2005-06-16	2009-09-01	Janssen Pharmaceutica N.V.	Tricyclic opioid modulators
US7557119B2 (en)	2005-07-21	2009-07-07	Rensselaer Polytechnic Institute	Large substituent, non-phenolic opioids
ES2459195T3 (es) *	2008-09-11	2014-05-08	Amgen Inc.	Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso
US8420647B2 (en)	2010-01-21	2013-04-16	Hoffmann-La Roche Inc.	4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
EP2547685A1 (de)	2010-03-15	2013-01-23	Amgen Inc.	Spiro-tetracyclische ringverbindungen als beta-sekretase-modulatoren
US8497264B2 (en)	2010-03-15	2013-07-30	Amgen Inc.	Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2673279A1 (de)	2011-02-07	2013-12-18	Amgen Inc.	5-amino-oxazepin- und 5-amino-thiazepanverbindungen als beta-sekretase-antagonisten und verwendungsverfahren
WO2013003720A1 (en)	2011-06-29	2013-01-03	Alkermes, Inc.	Peripherally acting opioid compounds
EP2758406A1 (de)	2011-09-21	2014-07-30	Amgen Inc.	Amino-oxazine und amino-dihydrothiazinverbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
WO2014078314A1 (en)	2012-11-15	2014-05-22	Amgen Inc.	Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN110013476A (zh) *	2019-04-08	2019-07-16	南昌大学	6-羟基-1,2,3,7-四甲氧基呫吨酮在制备促海马神经发生的药物中的应用
WO2021072083A1 (en) *	2019-10-08	2021-04-15	Marshall University Research Corporation	Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2368006A (en)	1943-10-07	1945-01-23	Searle & Co	Heterocyclic tertiary amines
US2784185A (en)	1953-03-27	1957-03-05	Promonta Chem Fab	Phenothiazine compounds
US2901478A (en)	1957-02-11	1959-08-25	Promonta Chem Fab	Phenothiazine compounds
US3179665A (en)	1959-12-16	1965-04-20	Wander Ag Dr A	9-(n-ethyl and n-propyl piperidyl-3'-methyl)-thioxanthenes
DE1159954B (de)	1961-11-25	1963-12-27	Boehringer & Soehne Gmbh	Verfahren zur Herstellung neuer 10-(Alkoxypiperidinopropyl)-phenthiazine und ihrer Salze
DE1670118A1 (de)	1966-07-22	1970-11-05	Boehringer Mannheim Gmbh	Verfahren zur Herstellung neuer Derivate des 6,11-Dihydro-dibenz[b,e]oxepins und ihrer Salze
US3470188A (en)	1967-01-05	1969-09-30	Smithkline Corp	9-cycloalkyl-lower alkyl-piperidylidene derivatives of xanthenes and thioxanthenes
NL6818027A (de)	1968-01-09	1969-07-11
GB1250534A (de)	1969-03-03	1971-10-20
US3987042A (en)	1969-03-03	1976-10-19	Claude Gueremy	Phenothiazine derivative
US3931232A (en)	1974-06-24	1976-01-06	Smithkline Corporation	3-Alkyl xanthene compounds
ZA756550B (en)	1974-11-06	1976-09-29	Smithkline Corp	Pharmaceutical compositions and method of producing antipsychotic activity without extrapyramidal symptoms
US4086350A (en)	1974-11-06	1978-04-25	Smithkline Corporation	Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
US4285956A (en)	1978-05-12	1981-08-25	Kefalas A/S	Xanthene and thioxanthene derivatives, compositions thereof and treatment therewith
US4356184A (en)	1980-06-04	1982-10-26	G. D. Searle & Co.	Anti-allergic or antihypertensive 1-piperidinylmethyl benzenamines
US4666907A (en)	1983-10-05	1987-05-19	Merck Frosst Canada, Inc.	Phenothiazine and derivatives and analogs and use as leukotriene biosynthesis inhibitors
US4777177A (en)	1984-10-19	1988-10-11	Ciba-Geigy Corporation	Pesticidal thioxanthen-9-ylidenepiperidines
FR2689013B1 (fr)	1992-03-30	1995-05-05	Rhone Poulenc Rorer Sa	Nouvelle application thérapeutique des dérivés de la phénothiazine.
ZA978792B (en)	1996-10-04	1998-04-06	Novo Nordisk As	N-substituted azaheterocyclic compounds.
SE9604786D0 (sv)	1996-12-20	1996-12-20	Astra Pharma Inc	New compounds
TW548271B (en)	1996-12-20	2003-08-21	Astra Pharma Inc	Novel piperidine derivatives having an exocyclic double bond with analgesic effects
WO1999000376A1 (en)	1997-06-25	1999-01-07	Novo Nordisk A/S	Novel heterocyclic compounds
US6040318A (en)	1997-06-25	2000-03-21	Novo Nordisk A/S	Tricycle substituted with azaheterocyclic carboxylic acids
ZA9811842B (en)	1997-12-24	2000-06-23	Ortho Mcneil Pharm Inc	4-[aryl(piperidin-4-yl)]aminobenzamides.
US6306876B1 (en)	1999-12-22	2001-10-23	Ortho-Mcneil Pharmaceutical, Inc.	4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives
KR20030009376A (ko)	2000-03-03	2003-01-29	오르토-맥네일 파마슈티칼, 인코퍼레이티드	3-(디아릴메틸렌)-8-아자비사이클로[3.2.1]옥탄 유도체
AU2001249250A1 (en)	2000-03-29	2001-10-08	Research Triangle Institute	Selective ligands for the delta opioid receptor
ES2239170T3 (es)	2000-10-31	2005-09-16	Rensselaer Polytechnic Institute	2,6-metano-3-benzazocinas sustituidas en posicion 8 y morfinanos sustituidos en posicion 3 como agentes ligantes a receptores opioides.
US6887876B2 (en)	2000-12-14	2005-05-03	Ortho-Mcneil Pharmaceutical, Inc.	Benzamidine derivatives
US6601009B2 (en)	2001-07-12	2003-07-29	Yahoo Inc	Method and system of automatic bandwidth detection
US7060711B2 (en)	2001-10-25	2006-06-13	Biofrontera Bioscience Gmbh	Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
EP1306376A1 (de)	2001-10-25	2003-05-02	Biofrontera Pharmaceuticals AG	Derivaten von 4-(Thio- oder Selenoxanthen-9-yliden)-Piperidin oder Acridine und ihre Verwendung als selektieven 5-HT2B antagonisten
EP1321169A1 (de)	2001-12-18	2003-06-25	Biofrontera Pharmaceuticals AG	Kombination eines Serotoninrezeptorantagonisten und eines Histidindcarboxylaseinhitors als Medizin
AU2003272362A1 (en)	2002-09-18	2004-04-08	Bayer Cropscience Ag	Insecticidal tricyclic derivatives
AU2003301299A1 (en)	2002-10-15	2004-05-04	Janssen Pharmaceutica, N.V.	Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
EP1615920A1 (de)	2003-04-15	2006-01-18	Pfizer Products Inc.	3-benzhydrylen-8-azabicyclo[3.2.1]octanderivate mit opioidrezeptoraktivität
US7589103B2 (en) *	2003-06-27	2009-09-15	Janssen Pharmaceutica N.V.	Tricyclic-bridged piperidinylidene derivatives as 8-opioid modulators
KR20080027216A (ko) *	2004-08-05	2008-03-26	얀센 파마슈티카 엔.브이.	트리사이클릭 δ-오피오이드 조절자
JP2008525483A (ja) *	2004-12-22	2008-07-17	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	三環式δ−オピオイド調節剤
CA2592462A1 (en)	2004-12-22	2006-06-29	Janssen Pharmaceutica N.V.	Tricyclic delta-opioid modulators
ATE432279T1 (de) *	2004-12-22	2009-06-15	Janssen Pharmaceutica Nv	Tricyclische delta-opioid-modulatoren
JP2008526878A (ja) *	2005-01-06	2008-07-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	三環式δ−オピオイド調節剤
US7582650B2 (en)	2005-06-16	2009-09-01	Janssen Pharmaceutica N.V.	Tricyclic opioid modulators

2006
- 2006-06-15 US US11/424,311 patent/US7582650B2/en not_active Expired - Fee Related
- 2006-06-15 BR BRPI0611885-2A patent/BRPI0611885A2/pt not_active Application Discontinuation
- 2006-06-15 RU RU2008101667/04A patent/RU2008101667A/ru not_active Application Discontinuation
- 2006-06-15 CA CA002612491A patent/CA2612491A1/en not_active Abandoned
- 2006-06-15 TW TW095121331A patent/TW200716134A/zh unknown
- 2006-06-15 WO PCT/US2006/023429 patent/WO2006138528A2/en not_active Ceased
- 2006-06-15 AU AU2006259273A patent/AU2006259273A1/en not_active Abandoned
- 2006-06-15 CN CNA2006800295853A patent/CN101243079A/zh active Pending
- 2006-06-15 EP EP06773315A patent/EP1896467B1/de not_active Not-in-force
- 2006-06-15 DE DE602006018604T patent/DE602006018604D1/de active Active
- 2006-06-15 AR ARP060102540A patent/AR057374A1/es unknown
- 2006-06-15 JP JP2008517127A patent/JP2008543866A/ja not_active Withdrawn
- 2006-06-15 AT AT06773315T patent/ATE490251T1/de not_active IP Right Cessation
2009
- 2009-07-10 US US12/500,706 patent/US20090275610A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN101243079A (zh)	2008-08-13
EP1896467B1 (de)	2010-12-01
TW200716134A (en)	2007-05-01
ATE490251T1 (de)	2010-12-15
EP1896467A2 (de)	2008-03-12
AR057374A1 (es)	2007-11-28
US20090275610A1 (en)	2009-11-05
US20060287297A1 (en)	2006-12-21
AU2006259273A1 (en)	2006-12-28
RU2008101667A (ru)	2009-07-27
WO2006138528A3 (en)	2007-03-15
WO2006138528A2 (en)	2006-12-28
CA2612491A1 (en)	2006-12-28
DE602006018604D1 (de)	2011-01-13
JP2008543866A (ja)	2008-12-04
US7582650B2 (en)	2009-09-01

Legal Events

Date	Code	Title	Description
2011-07-26	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2011-11-01	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]

Publication	Publication Date	Title
BRPI0611885A2 (pt)	2010-10-05	moduladores opióides tricìclicos
JP4810423B2 (ja)	2011-11-09	三環式デルタオピオイド調節剤
US20090291979A1 (en)	2009-11-26	Tricyclic-bridged piperidinylidene derivatives as delta opioid modulators
WO1995031455A1 (en)	1995-11-23	Quinolinecarboxylic acid derivative
EA011674B1 (ru)	2009-04-28	ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
JP2008525481A (ja)	2008-07-17	三環式δ−オピオイド・モジュレーター
JP2008526878A (ja)	2008-07-24	三環式δ−オピオイド調節剤
US7589104B2 (en)	2009-09-15	Tricyclic-bridged piperidinyline derivatives as §-opioid modulators
MX2007001557A (en)	2008-10-03	Tricyclic delta- opioid modulators
HK1097532B (en)	2010-04-16	Tricyclic delta opioid modulators
MXPA06000089A (en)	2006-12-13	Tricyclic delta opioid modulators
AU2011253957A1 (en)	2012-01-12	Tricyclic delta opioid modulators